highly significantP < 0.001
One study showed that the use of the Hepcon device resulted in a highly significant reduction in the total protamine dose compared to ACT-based dosing (mean protamine dose: 14.190 IU vs 24.777 IU; P < 0.001) and total blood loss (mean blood loss: 804 ml vs 1416 ml; P < 0.001) [ 495 ].